Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11547727 Chimeric antigen receptor-modified NK-92 cells

Patent 11547727 was granted and assigned to ImmunityBio on January, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Laurent H. Boissel0

Hans G. Klingemann0

Date of Patent

January 10, 2023

0

Patent Application Number

169691520

Date Filed

May 21, 2019

0

Patent Citations

US Patent 10138462 Natural killer cell lines and methods of use

Patent Citations Received

US Patent 11992504 Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

0

0

...

Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of FcεRIγ. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11547727 Chimeric antigen receptor-modified NK-92 cells

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool